| Targets |
MEK
|
|---|---|
| References | |
| Additional Infomation |
Mek-IN-6 is an orally bioavailable, blood-brain barrier-crossing mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK) inhibitor with potential antitumor activity. After oral administration, pofuritinib specifically targets, binds to, and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins (including extracellular signal-regulated kinases (ERKs)) and suppressing the proliferation of tumor cells with overactivated RAS/RAF/MEK/ERK signaling pathways. The threonine/tyrosine protein kinase MEK plays a crucial role in the RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in various tumor cell types and regulates key cellular activities including cell growth, proliferation, survival, differentiation, and apoptosis.
|
| Exact Mass |
393.115
|
|---|---|
| CAS # |
2845151-86-0
|
| Related CAS # |
MEK-IN-6 hydrate;2845153-35-5
|
| PubChem CID |
165386441
|
| Appearance |
White to light yellow solid powder
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
669
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
TURWFFGYNJNSFK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20FN3O4S/c1-21-15(24)9-11-5-6-22(26-8-7-23)18(25)16(11)17(21)20-14-4-3-12(27-2)10-13(14)19/h3-4,9-10,20,23H,5-8H2,1-2H3
|
| Chemical Name |
8-(2-fluoro-4-methylsulfanylanilino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~254.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05538130
Conditions:Melanoma|Glioma|Thyroid Cancer|Non-Small Cell Lung Cancer|Malignant Neoplasms|Brain Neoplasms|Advanced or Metastatic Solid Tumors|HGG|LGG|Low Grade Glioma|High Grade Glioma|Differentiated Thyroid Cancer|NSCLC (Non-small Cell Lung Cancer)Link: https://clinicaltrials.gov/ct2/show/NCT07563894
Conditions:Phase 1Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
